Nordwand Advisors’s Passage Bio PASG Stock Holding History

Nordwand Advisors’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-125	Closed	-$1.75K	–	132
2024 Q3	$1.75K	Buy	+125	New	+$1.99K	﹤0.01%	125

Other funds holding PASG

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nordwand Advisors's PASG Position: Q4 2024 in Review

Nordwand Advisors sold out of Passage Bio (PASG) in Q4 2024, closing a stake of 125 shares — an estimated $1.75K sold.

Nordwand Advisors first reported a position in PASG in Q3 2024 and held it in 1 quarter. The position peaked at $1.75K in Q3 2024. 44 funds tracked by Wall St. Rank hold PASG as of Q4 2024.

Nordwand Advisors reported no remaining Passage Bio position as of Q4 2024 after selling out during the quarter.
Nordwand Advisors sold 125 Passage Bio shares in Q4 2024, an estimated $1.75K.
Nordwand Advisors first reported a position in Passage Bio in Q3 2024 and held it in 1 quarter.
Nordwand Advisors's Passage Bio position peaked at $1.75K in Q3 2024.
44 funds tracked by Wall St. Rank held Passage Bio as of Q4 2024.

Based on Nordwand Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.